Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma

There are many different chronic respiratory diseases. Verona Pharma is mainly focused on two diseases: asthma and COPD. Asthma is a very common disease and unfortunately it has been increasing in prevalence in developed countries. This is the same with COPD; however, there may be different reasons for this.

25 Sep 2012

FDA forms new internal task force to support development of new antibacterial drugs

The U.S. Food and Drug Administration today announced the formation of an internal task force that will support the development of new antibacterial drugs, a critical public health care goal and a priority for the agency.

25 Sep 2012

Ciprofloxacin use is major contributor to MRSA spread in hospitals

The use of a commonly prescribed antibiotic is a major contributor to the spread of infection in hospitals by the 'superbug' MRSA, according to new research. The study also found that increasing measures to prevent infection - such as improved hygiene and hand washing - appeared to have only a small effect on reducing MRSA infection rates during the period studied.

21 Sep 2012

TECHLAB to utilize Dynex's Gold SmartKit packaging for ELISA product line

Dynex Technologies, Inc. announced today it has finalized a supply agreement with TECHLAB, Inc. (Blacksburg, VA), allowing TECHLAB to utilize Dynex's Gold SmartKit packaging for their ELISA product line.

20 Sep 2012

FDA warns consumers not to use Intestinomicina for treatment of infectious diarrhea

The U.S. Food and Drug Administration is warning consumers not to use Intestinomicina, a drug product manufactured in El Salvador and marketed as a treatment for infectious diarrhea and acute gastrointestinal infections.

19 Sep 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

Study finds identical strains of antibiotic-resistant C. coli in ABF and conventionally raised pigs

Researchers from North Carolina State University have found identical strains of antibiotic-resistant Campylobacter coli (C. coli) in both antibiotic-free (ABF) and conventionally raised pigs.

18 Sep 2012

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received FDA clearance for a new molecular diagnostic test for Group A Streptococcus on the illumigene platform.

18 Sep 2012

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

17 Sep 2012

Natural antibiotic to treat tuberculosis

A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown how pyridomycin, a natural antibiotic produced by the bacterium Dactylosporangium fulvum, works.

17 Sep 2012

ASN's top five recommendations to avoid wasteful and harmful medical interventions

Earlier this year, the American Society of Nephrology (ASN), the world's leading kidney organization, joined other groups in a campaign to help health care professionals and patients avoid wasteful and sometimes harmful medical interventions. A new article in the Clinical Journal of the American Society of Nephrology (CJASN) outlines the ASN's top five recommendations for the campaign and the rationale behind them.

14 Sep 2012

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announce the availability of a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health.

14 Sep 2012

Nature examines efforts to combat antibiotic resistance in India

Nature examines efforts to combat antibiotic resistance in India, writing, "Antibiotic resistance is a problem worldwide, but is particularly worrying in India, where hospital standards are inconsistent and antibiotics are readily available over the counter at pharmacies."

13 Sep 2012

Case Western Reserve researcher discovers new antivirulence drugs against MRSA and strep

Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, has discovered novel antivirulence drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) and Streptococcus pyogenes, commonly referred to as strep, harmless by preventing the production of toxins that cause disease.

13 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Novel method could help advance fight against persistent 'HIV latency'

Scientists at the Gladstone Institutes have gotten us one step closer to understanding and overcoming one of the least-understood mechanisms of HIV infection-by devising a method to precisely track the life cycle of individual cells infected with HIV, the virus that causes AIDS.

12 Sep 2012

New model reveals how immune system functions under conditions of neutropenia

Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the number of white blood cells falls below a critical threshold, the risk of infection is thought to be high.

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

11 Sep 2012

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of two major grants for the development of monoclonal antibody therapeutics against nosocomial infections.

11 Sep 2012

Antibiotic News and Research

Further Reading

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma

FDA forms new internal task force to support development of new antibacterial drugs

Ciprofloxacin use is major contributor to MRSA spread in hospitals

TECHLAB to utilize Dynex's Gold SmartKit packaging for ELISA product line

FDA warns consumers not to use Intestinomicina for treatment of infectious diarrhea

Friendly bacteria: do we really need to eat probiotic yogurts?

Study finds identical strains of antibiotic-resistant C. coli in ABF and conventionally raised pigs

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Natural antibiotic to treat tuberculosis

ASN's top five recommendations to avoid wasteful and harmful medical interventions

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Nature examines efforts to combat antibiotic resistance in India

Case Western Reserve researcher discovers new antivirulence drugs against MRSA and strep

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Novel method could help advance fight against persistent 'HIV latency'

New model reveals how immune system functions under conditions of neutropenia

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News